SCHEMBL1053699

SCHEMBL1053699

CN(C(=O)c1ccccc1)c1ccc2c(ccn2C(=O)OC(C)(C)C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ NR1H2 P55055 2/20 0.40
▸ NR1H3 Q13133 1/20 0.40
▸ PIK3CD O00329 2/20 0.39
▸ ABL1 P00519 2/20 0.39
▸ EGFR P00533 2/20 0.39
▸ HCK P08631 2/20 0.39
▸ SRC P12931 2/20 0.39
▸ KDR P35968 2/20 0.39
▸ PIK3CA P42336 2/20 0.39
▸ PIK3CB P42338 2/20 0.39
▸ MTOR P42345 2/20 0.39
▸ PIK3CG P48736 2/20 0.39
▸ EPHB4 P54760 2/20 0.39
▸ PRKDC P78527 2/20 0.39
▸ PI4KB Q9UBF8 2/20 0.39
▸ ITK Q08881 5/20 0.39
▸ INSR P06213 1/20 0.39
▸ TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4719272 0.84 ITK (0.43) KMT2ANR1H2NR1H3EGFRITK
SCHEMBL10117911 0.78 PIK3CD (0.43) NR1H2NR1H3PIK3CDABL1EGFR
SCHEMBL3835028 0.77 MAPT (0.43) KMT2AMEN1NR1H2PIK3CDABL1
SCHEMBL2458509 0.77 ACLY (0.52) NR1H2NR1H3PIK3CDABL1EGFR
SCHEMBL15969036 0.77 PPARG (0.43) NR1H2NR1H3PIK3CDABL1EGFR
SCHEMBL6394140 0.76 PIK3CD (0.45) PIK3CDABL1EGFRHCKSRC
SCHEMBL17782354 0.76 NR1H2 (0.42) NR1H2NR1H3PIK3CDABL1EGFR
SCHEMBL5482233 0.76 HTR6 (0.41) KMT2AMEN1NR1H2NR1H3PIK3CD
SCHEMBL1053697 0.76 ALDH1A1 (0.46) NR1H2PIK3CDABL1EGFRHCK
SCHEMBL691666 0.74 NOTUM (0.59) NR1H2NR1H3PIK3CDABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8691814-B2 Deazapurines and uses thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-04-08 — — US disclosed
US-20110105427-A1 DEAZAPURINES AND USES THEREOF DAUN JANE 2011-05-05 — — US disclosed
US-7868002-B2 Deazapurines and uses thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-01-11 — — US disclosed
EP-1474425-B9 DEAZAPURINES AND USES THEREOF EISAI CO LTD (JP) 2008-07-02 — — EP disclosed
US-20080103137-A1 Deazapurines and uses thereof EISAI CO., LTD. 2008-05-01 — — US disclosed
US-7314936-B2 Deazapurines and uses thereof EISAI CO., LTD. (JP) 2008-01-01 — — US disclosed
EP-1707566-A1 Deazapurines and uses thereof Eisai Co., Ltd. (JP) 2006-10-04 — — EP disclosed
EP-1474425-B1 DEAZAPURINES AND USES THEREOF EISAI CO LTD (JP) 2006-05-24 — — EP disclosed
US-20050124649-A1 Deazapurines and uses thereof EISAI CO., LTD (JP) 2005-06-09 — — US disclosed
EP-1474425-A1 DEAZAPURINES AND USES THEREOF Eisai Co. Ltd. (JP) 2004-11-10 — — EP disclosed
US-20040186127-A1 Novel deazapurines and uses thereof EISAI CO., LTD. (JP) 2004-09-23 — — US disclosed
WO-2003057696-A1 DEAZAPURINES AND USES THEREOF EISAI CO. LTD. (JP) 2003-07-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105427-A1 DEAZAPURINES AND USES THEREOF TPMT, CD38, CD2 KMT2A 1590/4885MEN1 3643/4885NR1H2 3913/4885
US-20050124649-A1 Deazapurines and uses thereof TPMT, CD38, CD2 KMT2A 1654/4885MEN1 3746/4885NR1H2 3946/4885
US-20080103137-A1 Deazapurines and uses thereof TPMT, TYMP, ENTPD5 KMT2A 963/4885MEN1 3607/4885NR1H2 1772/4885
US-20040186127-A1 Novel deazapurines and uses thereof TPMT, ENTPD5, MTAP KMT2A 2445/4885MEN1 3362/4885NR1H2 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback